About NEUROPHET
NEUROPHET is a publicly listed company based in Seoul (South Korea) founded in 2016 by Donghyeon Kim and Junkil Been. It operates as an AI-based simulation software for electrical brain stimulation is developed. It operates in the Healthcare and Technology sectors. NEUROPHET has raised $24.4 million across 5 funding rounds from investors including Shinhan Bank, SBI Investment Korea and Samjin Pharm. Its chief executive is Donghyeon Kim. Its website neurophet.com draws about 12 thousand monthly visits. Its focus areas include HealthTech, Healthcare IT, Provider and Clinical Operations. Its legal entity is Neurofit Co., Ltd. Its competitors include Viz.ai, icometrix, RapidAI, Jvion and BrainSightAI and 3 more; 8 of its 8 listed competitors have raised funding.
Company details
NEUROPHET was founded in 2016 in Seoul, South Korea, within the neuro-engineering sector. AI-based simulation software is provided for doctors and researchers focused on electrical brain stimulation. Individual 3D brain models are generated automatically from MRI scans for each patient. Effects of stimulation under various treatment parameters are simulated and analyzed in clinical environments to support medical decision-making.
- Headquarters Seoul, South Korea
- Founders Donghyeon Kim, Junkil Been
- Stage Public
- SectorsHealthcareTechnology
- Email••••••••
- Phone•••• ••••
- Website neurophet.com/en
- Social LinkedIn Facebook
- Legal Name Neurophet, Inc.
- Annual Revenue$1.81 M (USD)18as on Dec 31, 2025
- Net Profit-$15.5 M (USD)-48.26as on Dec 31, 2025
- EBITDA-$10.69 M (USD)-13.91as on Dec 31, 2025
- Total Equity Funding$24.4M (USD)
in 5 rounds
- InvestorsShinhan Bank
& 11 more
Funding Insights of NEUROPHET
NEUROPHET has successfully raised a total of $24.4M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $24.4M
- Total Rounds 5
- First Round $5.1M
(Nov 2019)
- Investors Count 12
All 5 funding rounds of NEUROPHET with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2026 | $21.54M | Post-IPO | – | – | GVA,Fine Value Asset Management |
| Mar 2024 | $751,371 | Series B | – | Samjin Pharm | – |
| Nov 2021 | $16M | Series B | – | SBI Investment Korea, Kolon Investments | – |
| Jan 2020 | $2.54M | Series A | – | SBI Investment Korea | – |
| Nov 2019 | $5.1M | Series A | – | ES Investor, Magellan Technology Investment |
12 investors in total: 12 institutional.
Investors in NEUROPHET
NEUROPHET has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Shinhan Bank, SBI Investment Korea and Samjin Pharm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sector-agnostic VC firm investing in geographies such as South Korea | 1986 | sbik.co.kr | Seoul, South Korea | |
Venture capital and private equity are invested in various sectors. | – | koloninvest.com | Seoul, South Korea | |
Private equity investments in South Korea are managed. | – | investwells.com | Seoul, South Korea | |
Venture capital funding is provided to companies making positive impacts. | – | esinvestor.com | Seoul, South Korea | |
- | – | jcurveinvest.com | - | |
- | – | mtivc.com | - | |
Tech startups are funded by Daedeok Venture Partners. | – | dvpdvp.com | Yuseong District, South Korea | |
- | – | leoi.co.kr | - | |
Provides comprehensive marketing and branding services to drive business growth. | 2016 | futureplay.in | India | |
Commercial banking services are provided to retail and corporate clients. | 1982 | shinhan.com | Seoul, South Korea |
Investor details for NEUROPHET
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NEUROPHET
2 people are tracked at NEUROPHET (2 in leadership).
| Name | Role | Group |
|---|---|---|
Donghyeon Kim | Co-Founder, Co-CEO & CTO | Leadership |
Junkil Been | Co-Founder & Co-CEO | Leadership |
Complete people profiles for NEUROPHET
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NEUROPHET
NEUROPHET is a publicly listed company on the KRX with ticker symbol 380550 in South Korea, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jul 2025
- Listed onKRX: 380550
- Listed entityNeurophet, Inc.
- Exchange sectorTechnology services
- ISINKR7380550004
- Share price6,300.00 KRW (+2.11% on the day) · 2026-10-14
- Market capitalisation75,267,002,544.00 KRW
- EPS (diluted, trailing year)-1,886.15 KRW
- Volume (last session)39,736
Financials of NEUROPHET
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.62B KRW | -22.39B KRW | -15.44B KRW |
| 2024 | 2.22B KRW | -15.10B KRW | -13.55B KRW |
| 2023 | 1.56B KRW | 5.26B KRW | -10.74B KRW |
| 2022 | 647.3M KRW | -18.32B KRW | -8.43B KRW |
Detailed financial statements for NEUROPHET
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NEUROPHET
4 dated milestones of NEUROPHET across 10 years, from founding to its latest funding, stage changes and deals.
- Founded NEUROPHET is founded.
- Funding First funding round of $5.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
Competitors of NEUROPHET
NEUROPHET has 8 listed competitors in our database, 8 of them funded. They include Viz.ai, icometrix, RapidAI, Jvion and BrainSightAI, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viz.ai | 2016 | San Francisco, United States | $251.99M | 206 | AI and cloud-powered software for stroke care coordination is developed. | |
| icometrix.com | 2011 | Leuven, Belgium | $20.18M | 37 | AI-based software for brain MRI analysis is provided by icometrix. | |
| rapidai.com | 2012 | San Mateo, United States | $100M | – | Provider of AI-based neuroimaging software for physicians | |
| jvion.com | 2011 | Suwanee, United States | $11.12M | – | Deep learning-based illness prediction solutions are provided by Jvion. | |
| brainsightai.com | 2019 | Bengaluru, India | $6.67M | 41 | Functional brain mapping is enabled by AI-driven connectomics platform. | |
| braintale.eu | 2018 | Strasbourg, France | $6.1M | – | AI-based brain assessment and disease diagnosis are provided for providers. | |
| cerebriu.com | 2018 | Copenhagen, Denmark | $29.52M | 29 | AI-based imaging software is utilized for brain disease diagnosis. | |
| pixyl.ai | 2015 | La Tronche, France | $3.19M | – | AI tools for neuroimage analysis are developed for clinicians. |
Detailed competitors of NEUROPHET
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NEUROPHET
The website of NEUROPHET (neurophet.com) receives about 11.7K visits a month.
- Monthly visits11.7K
▼ 37.7% vs previous month
Top companies in Clinical IT & Data Platforms
10 companies that operate in the same segment as NEUROPHET (Clinical IT & Data Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of fitness memberships encompassing group classes, gyms, and at-home workouts | 2016 | Bengaluru, Karnataka, India | USD 716.99 M | – | 1,832 | |
Employee health benefits are facilitated via a cloud-based platform. | 2007 | Plymouth Meeting, Pennsylvania, United States | USD 228.3 M | – | – | |
Healthcare appointments are booked online via Zocdoc's platform. | 2007 | New York, New York, United States | USD 425.97 M | USD 4.66 M | 1,365 | |
Virtual physical therapy and digital pain care solutions are provided. | 2015 | San Francisco, California, United States | USD 854.44 M | – | 1,746 | |
Tech-enabled mental health solutions for employers are provided. | 2016 | New York, New York, United States | USD 473.73 M | – | 3,902 | |
App-based health insurance is offered to individuals and businesses. | 2016 | Paris, Ile de France, France | USD 863.12 M | – | 1,606 | |
Virtual care programs for managing chronic diseases are provided. | 2011 | San Francisco, California, United States | USD 450.12 M | USD 260.21 M | 992 | |
AI-driven EMR and practice management software is delivered for clinics. | 2010 | Boca Raton, Florida, United States | USD 329.17 M | – | 2,470 | |
Cloud-based administrative tools for healthcare providers are offered. | 1997 | Watertown, United States | USD 40 M | – | – | |
Membership-based primary care platform is offered for employees and consumers. | 2007 | San Francisco, California, United States | USD 402.56 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Neurophet
Complete news archive for NEUROPHET
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NEUROPHET
NEUROPHET was founded in 2016 and raised its 1st funding round 3 years after it was founded.
NEUROPHET is headquartered in Seoul, South Korea.
Donghyeon Kim is the current CEO of NEUROPHET. They have also founded this company.
NEUROPHET is a funded company, having raised a total of $24.4M across 5 funding rounds to date. The company's 1st funding round was a Series A of $5.1M, raised on Nov 2019.
Annual revenue of NEUROPHET is $1.81M as on Dec 31, 2025.
NEUROPHET was founded in 2016 in Seoul, South Korea, within the neuro-engineering sector. AI-based simulation software is provided for doctors and researchers focused on electrical brain stimulation. Individual 3D brain models are generated automatically from MRI scans for each patient. Effects of stimulation under various treatment parameters are simulated and analyzed in clinical environments to support medical decision-making.
NEUROPHET's top competitors include Viz.ai, BrainSightAI and RapidAI.
Yes, NEUROPHET is publicly traded on KRX under the ticker symbol 380550.
NEUROPHET has 12 investors. Key investors include Shinhan Bank, SBI Investment Korea, Samjin Pharm, Future Play, and Kolon Investments.
NEUROPHET operates through Neurofit Co., Ltd..